Prevention of nodal metastases in breast cancer following the lymphatic migration of paclitaxel-loaded expansile nanoparticles

Biomaterials

Volumn 34, Issue 7, 2013, Pages 1810-1819

  Liu, Rong ^a   Gilmore, Denis M ^a   Zubris, Kimberly Ann V ^b   Xu, Xiaoyin ^a   Catalano, Paul J ^c   Padera, Robert F ^a   Grinstaff, Mark W ^b   Colson, Yolonda L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON UNIVERSITY   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Drug delivery; Lymphatic; Metastases; Nanoparticle; Polymer

Indexed keywords

AXILLARY LYMPH NODES; BREAST CANCER; BREAST CANCER MODELS; DOSE-DEPENDENT; IN-VITRO; IN-VIVO; LOCOREGIONAL CONTROL; LOCOREGIONAL RECURRENCE; LYMPH NODE; LYMPH NODE METASTASIS; LYMPHATIC; METASTASES; METASTATIC DISEASE; NODAL METASTASIS; PACLITAXEL; TARGETED DELIVERY; TARGETED DRUG DELIVERY; TRIPLE NEGATIVE; TUMOR CELLS; TUMOR DOUBLING TIME; TUMOR GROWTH;

BODY FLUIDS; CHEMOTHERAPY; DISEASES; DRUG DELIVERY; NANOPARTICLES; PATHOLOGY; PATIENT MONITORING; POLYMERS; TUMORS;

DIAGNOSIS;

NANOPARTICLE; PACLITAXEL;

ANIMAL EXPERIMENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CYTOTOXICITY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; LYMPH NODES; MICE; MICROSCOPY, CONFOCAL; NANOPARTICLES; NEOPLASM METASTASIS; PACLITAXEL;

MURINAE;

EID: 84871064705     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.11.038     Document Type: Article

References (41)

1. Forouzanfar M.H., Foreman K.J., Delossantos A.M., Lozano R., Lopez A.D., Murray C.J., et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011, 378:1461-1484.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. Fisher B., Jeong J.H., Anderson S., Bryant J., Fisher E.R., Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002, 347:567-575.
4. Fleissig A., Fallowfield L.J., Langridge C.I., Johnson L., Newcombe R.G., Dixon J.M., et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 2006, 95:279-293.
5. Schrenk P., Rieger R., Shamiyeh A., Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000, 88:608-614.
6. Krag D.N., Anderson S.J., Julian T.B., Brown A.M., Harlow S.P., Costantino J.P., et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010, 11:927-933.
7. Weaver D.L., Ashikaga T., Krag D.N., Skelly J.M., Anderson S.J., Harlow S.P., et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 2011, 364:412-421.
8. Clarke M., Collins R., Darby S., Davies C., Elphinstone P., Evans E., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366:2087-2106.
9. Darby S., McGale P., Correa C., Taylor C., Arriagada R., Clarke M., et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011, 378:1707-1716.
10. Chen J., Wang L., Yao Q., Ling R., Li K., Wang H. Drug concentrations in axillary lymph nodes after lymphatic chemotherapy on patients with breast cancer. Breast Cancer Res 2004, 6:R474-R477.
11. Colson Y.L., Liu R., Southard E.B., Schulz M.D., Wade J.E., Griset A.P., et al. The performance of expansile nanoparticles in a murine model of peritoneal carcinomatosis. Biomaterials 2011, 32:832-840.
12. Khullar O.V., Griset A.P., Gibbs-Strauss S.L., Chirieac L.R., Zubris K.A., Frangioni J.V., et al. Nanoparticle migration and delivery of paclitaxel to regional lymph nodes in a large animal model. J Am Coll Surg 2012, 214:328-337.
13. Griset A.P., Walpole J., Liu R., Gaffey A., Colson Y.L., Grinstaff M.W. Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an acid-responsive polymeric drug delivery system. J Am Chem Soc 2009, 131:2469-2471.
14. Jenkins D.E., Hornig Y.S., Oei Y., Dusich J., Purchio T. Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res 2005, 7:R444-R454.
15. Yen M.S., Juang C.M., Lai C.R., Chao G.C., Ng H.T., Yuan C.C. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynaecol Obstet 2001, 72:55-60.
16. Sparreboom A., Scripture C.D., Trieu V., Williams P.J., De T., Yang A., et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (taxol). Clin Cancer Res 2005, 11:4136-4143.
17. Moghimi S.M., Hunter A.C., Andresen T.L. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol 2011, 52:481-503.
18. Davis M.E., Chen Z., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
19. Wang A.Z., Langer R.S., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu Rev Med 2011, 63:185-198.
20. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nature Rev Drug Discov 2005, 4:145-160.
21. Blanco E., Hsiao A., Ruiz-Esparza G.U., Landry M.G., Meric-Bernstam F., Ferrari M. Molecular-targeted nanotherapies in cancer: enabling treatment specificity. Mol Oncol 2011, 5:492-503.
22. Li T., Hu W., Liu Y., Huang G., Sumer B.D., Gao J. Shape-specific polymeric nanomedicine: emerging opportunities and challenges. Exp Biol Med 2011, 236:20-29.
23. Ernsting M.J., Tang W.L., MacCallum N.W., Li S.D. Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models. Biomaterials 2012, 33:1445-1454.
24. Wang X., Zhao G., Van S., Jiang N., Yu L., Vera D., et al. Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts. Cancer Chemother Pharmacol 2010, 65:515-526.
25. Yang Q., Wang S., Fan P., Wang L., Di Y., Lin K., et al. pH-Responsive carrier system based on carboxylic acid modified mesoporous silica and polyelectrolyte for drug delivery. Chemistry of Materials 2005, 17:5999-6003.
26. Thistlethwaite A.J., Leeper D.B., Moylan D.J., Nerlinger R.E. pH distribution in human tumors. Int J Radiat Oncol Biol Phys 1985, 11:1647-1652.
27. Kallinowski F., Vaupel P. pH distributions in spontaneous and isotransplanted rat tumours. Br J Cancer 1988, 58:314-321.
28. Coleman R.L., Brady W.E., McMeekin D.S., Rose P.G., Soper J.T., Lentz S.S., et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol 2011, 122:111-115.
29. Sawicki J.A., Anderson D.G., Langer R. Nanoparticle delivery of suicide DNA for epithelial ovarian cancer therapy. Adv Exp Med Biol 2008, 622:209-219.
30. Sloat B.R., Sandoval M.A., Li D., Chung W.G., Lansakara P.D., Proteau P.J., et al. In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles. Int J Pharm 2011, 409:278-288.
31. Werner M.E., Karve S., Sukumar R., Cummings N.D., Copp J.A., Chen R.C., et al. Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. Biomaterials 2011, 32:8548-8554.
32. Deng Z., Zhen Z., Hu X., Wu S., Xu Z., Chu P.K. Hollow chitosan-silica nanospheres as pH-sensitive targeted delivery carriers in breast cancer therapy. Biomaterials 2011, 32:4976-4986.
33. Luo G., Yu X., Jin C., Yang F., Fu D., Long J., et al. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm 2010, 385:150-156.
34. Yang F., Jin C., Yang D., Jiang Y., Li J., Di Y., et al. Magnetic functionalised carbon nanotubes as drug vehicles for cancer lymph node metastasis treatment. Eur J Cancer 2011, 47:1873-1882.
35. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007, 25:1159-1164.
36. Rao D.A., Forrest M.L., Alani A.W., Kwon G.S., Robinson J.R. Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery. J Pharm Sci 2010, 99:2018-2031.
37. Azab A.K., Kleinstern J., Doviner V., Orkin B., Srebnik M., Nissan A., et al. Prevention of tumor recurrence and distant metastasis formation in a breast cancer mouse model by biodegradable implant of 131I-norcholesterol. J Control Release 2007, 123:116-122.
38. Lu B., Xiong S.B., Yang H., Yin X.D., Chao R.B. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases. Eur J Pharm Sci 2006, 28:86-95.
39. Cai S., Xie Y., Bagby T.R., Cohen M.S., Forrest M.L. Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. J Surg Res 2008, 147:247-252.
40. Cohen M.S., Cai S., Xie Y., Forrest M.L. A novel intralymphatic nanocarrier delivery system for cisplatin therapy in breast cancer with improved tumor efficacy and lower systemic toxicity in vivo. Am J Surg 2009, 198:781-786.
41. Cai S., Xie Y., Davies N.M., Cohen M.S., Forrest M.L. Carrier-based intralymphatic cisplatin chemotherapy for the treatment of metastatic squamous cell carcinoma of the head & neck. Ther Deliv 2010, 1:237-245.